Deutsche Bank Ag\ Kronos Bio, Inc. Transaction History

Deutsche Bank Ag\

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.24 - $1.92 $42,189 - $65,326	-34,024 Reduced 68.81%	15,423 $26,000
Q1 2023 May 15, 2023	SELL	$1.34 - $2.62 $90,254 - $176,467	-67,354 Reduced 57.67%	49,447 $72,000
Q4 2022 Feb 13, 2023	BUY	$1.44 - $3.44 $391 - $935	272 Added 0.23%	116,801 $189,000
Q3 2022 Nov 14, 2022	SELL	$3.35 - $5.55 $88,778 - $147,080	-26,501 Reduced 18.53%	116,529 $391,000
Q2 2022 Aug 11, 2022	BUY	$3.12 - $7.52 $65,679 - $158,303	21,051 Added 17.26%	143,030 $520,000
Q1 2022 May 13, 2022	SELL	$6.26 - $14.42 $15,637 - $36,021	-2,498 Reduced 2.01%	121,979 $882,000
Q4 2021 Feb 11, 2022	BUY	$11.35 - $21.18 $1.15 Million - $2.15 Million	101,630 Added 444.83%	124,477 $1.69 Million
Q3 2021 Nov 04, 2021	SELL	$18.17 - $24.7 $13,064 - $17,759	-719 Reduced 3.05%	22,847 $479,000
Q2 2021 Aug 11, 2021	BUY	$20.08 - $29.02 $274,774 - $397,109	13,684 Added 138.47%	23,566 $564,000
Q1 2021 May 13, 2021	SELL	$27.0 - $32.48 $23,463 - $28,225	-869 Reduced 8.08%	9,882 $289,000
Q4 2020 Feb 16, 2021	BUY	$26.68 - $38.23 $286,836 - $411,010	10,751 New	10,751 $321,000

20.7M

31.4K

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $53.4M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.